HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Thierry Bové Yves Van Belleghem Katrien François Guido J Van Nooten Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tamim, M. Articles by Van Nooten, G. J Search for Related Content PubMed PubMed Citation Articles by Tamim, M. Articles by Van Nooten, G. J Related Collections Valve disease

Aortic Valve Replacement with Toronto SPV in Elderly Patients: 10-Year Results

Heart Center, University Hospital of Ghent, Ghent, Belgium

For reprint information contact: Thierry Bové, MD Tel: 32 9 240 4700 Fax: 32 9 240 3882 Email: thierry.bove{at}ugent.be, Cardiac Surgery Department, University Hospital of Ghent, 185 De Pintelaan, 5K12 9000, Ghent, Belgium.

A retrospective assessment of clinical and echocardiographic variables was performed in 145 patients who received a Toronto SPV aortic valve replacement. The majority (90%) of these elderly patients (mean age, 75.5 ± 7.4 years) were preoperatively in New York Heart Association class III–IV. Operative mortality was 4.8%. Follow-up was complete up to 10 years and revealed few valve-related complications: thromboembolism (7), bleeding (4), and prosthesis dysfunction necessitating reoperation (3). Late mortality was cardiac-related in 11.7% and noncardiac-related in 17.2%. Actuarial survival was 83% at 5 years and 63% at 8 years. Echocardiography showed low transvalvular gradients (peak, 17.5 ± 7.5 mm Hg; mean, 9.2 ± 4.2 mm Hg) resulting in a significant reduction in left ventricular mass index during the first 3 years. Independent of the transprosthetic gradient, left ventricular mass index tended to increase again beyond the 5th year, which correlated positively with the presence of arterial hypertension in this older population. The Toronto SPV bioprosthesis offers an aortic valve substitute with excellent long-term hemodynamics, resulting in significant early left ventricular mass regression. Considering the limitations of this selected elderly population, the clinical outcome and survival up to 10 years are encouraging, with few observed valve-related events.

This article has been cited by other articles:

				P. Stelzer Stentless Aortic Valve Replacement: Porcine and Pericardial Card. Surg. Adult, January 1, 2008; 3(2008): 915 - 934. [Full Text]